Iridex to Report Fourth Quarter and Full Year 2025 Financial Results on March 26, 2026
Rhea-AI Summary
Iridex (Nasdaq: IRIX) will report fourth quarter and full year 2025 financial results on March 26, 2026 after market close and provide a business update.
Management will host a conference call on March 26, 2026 at 2:00 p.m. PT / 5:00 p.m. ET with live and recorded webcast access on the company website.
Positive
- None.
Negative
- None.
News Market Reaction – IRIX
In the Mar 13 session, IRIX declined 2.26%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 02 | Headquarters relocation | Positive | +0.3% | Planned HQ move aiming for operating cost savings and efficiency. |
| Jan 12 | Preliminary 2025 results | Positive | +28.7% | Preliminary 2025 revenue growth, positive cash flow, and positive adjusted EBITDA. |
| Dec 11 | Glaucoma retreatment study | Positive | +3.4% | Independent study showing safe, effective MicroPulse retreatment for glaucoma. |
| Dec 08 | Thermal dynamics study | Positive | -1.7% | Modeling study supporting MicroPulse vs continuous-wave glaucoma laser profiles. |
| Dec 05 | Investor conference appearance | Neutral | +1.2% | Participation in Sidoti virtual conference to provide company updates. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
IRIX has generally traded higher on positive operational and clinical news, with one recent divergence on a technical study update.
Recent updates show IRIX balancing operational efficiency, growth, and clinical validation. On Feb 02, 2026, it announced a headquarters move targeting savings of $0.4M in fiscal 2026 and $0.6M annualized. Preliminary Q4 and 2025 results on Jan 12, 2026 highlighted Q4 revenue of $14.6M–$14.8M and full-year revenue of $52.5M–$52.7M, with positive cash flow and expected positive adjusted EBITDA. December 2025 brought supportive glaucoma data and visibility via an investor conference. Today’s earnings-date notice fits this ongoing communication cadence.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MOUNTAIN VIEW, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced plans to release financial results for the fourth quarter and full year 2025 and provide a business update after the close of trading on March 26, 2026.
The Company’s management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing +1-646-307-1963 from the US or +1-800-715-9871 internationally and providing Conference ID: 3693990. A live and recorded webcast will be available on the “Event Calendar” page of the “Investors” section of the Company’s website at www.iridex.com.
About Iridex Corporation
Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated laser treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com.
MicroPulse® is a registered trademark of Iridex Corporation, Inc. in the United States, Europe and other jurisdictions. © 2026 Iridex Corporation. All rights reserved.
Investor Relations Contact
Philip Taylor
Gilmartin Group
investors@iridex.com
